NCT07052539Recruiting
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
Source: ClinicalTrials.gov · Last updated 4 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 26 Jun 2025
- Start date
- 22 Jul 2022
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University of Mississippi Medical Center
- Diseases
- Chronic kidney disease, Heart failure, Obesity
- NCT number
- NCT07052539
What you commit to
- Study type: Observational
- Planned participants: 60
- From 22 Jul 2022 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of nicotine or recreational drugs, chronic drinker
- Criteria for Cohort 2: Obese Participants without HFpEF
- Current use of nicotine or recreational drugs, chronic drinker
- Criteria for Cohort 3: HFpEF and Obese Participants
- Current use of nicotine or recreational drugs, chronic drinker
Other illness
- Diagnosis of chronic illness
- History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- Acute illness or hospitalization event within 3 months
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- Diagnosis of Heart Failure
- Diagnosis of chronic illness
- History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- Acute illness or hospitalization event within 3 months
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- History of RRT or kidney transplant
- Acute illness/hospitalization in the past 3 months
- History of cancer, chemo, or XRT
- History of allergies to contrast
- Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
Lab values
- eGFR\<60mL/min/1.73m2
- Hemoglobin levels \<7mg/dL
- eGFR\<60mL/min/1.73m2
- Hemoglobin levels \<7mg/dL
- Hemoglobin \< 7
Other
- Pregnancy or breast feeding
- Unable to stop NSAIDs
- Pregnancy or breast feeding
- Unable to stop NSAIDs
- NYHA class III/IV
- Urinary retention screen +
- Mobility issues
- Pregnant/breastfeeding
- Unable to stop NSAIDs
Who the study is looking for
- Adults 18-75 years old
- Normal kidney function
- No heart failure
- BMI 25-30kg/m2
- Adults 18-75 years old
- eGFR \>= 60 mL/min/1.73m2
- BMI \> 35 kg/m2
- Adults 18-75 years old
- eGFR \>= 60 mL/min/1.73m2
- BMI \> 35 kg/m2
- Diagnosis of HFpEF (chart diagnosis, LVEF \> 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6
Criteria the registry did not label
- Criteria for Cohort 1: Healthy Participants
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Mississippi Medical Center Coordinator of this site? Confirm its status | Jackson | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.